BASEL (dpa-AFX) - Genmab A/S (GMXAY.PK, GNMSF.OB) said that its
collaboration partner Novartis will start Phase III studies of the subcutaneous
formulation of ofatumumab in relapsing multiple sclerosis or MS with enrolment
of patients expected to...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.